News

BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer’s drug

0

Biogen’s new Alzheimer’s drug aduhelm saw limited pickup in its first few months on the market.

Storm expected to glaze Pennsylvania, New England in ice

Previous article

Wall Street analysts see a big year ahead for Amazon after fourth-quarter earnings beat

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News